Acquisition by Seidel-dugan Cynthia of 79516 shares of Werewolf Therapeutics at 11.55 subject to Rule 16b-3
| BSEM Stock | USD 15.49 0.49 3.27% |
About 55% of Biostem Technologies' investors are presently thinking to get in. The analysis of current outlook of investing in Biostem Technologies suggests that some traders are interested regarding Biostem Technologies' prospects. Biostem Technologies' investing sentiment overview a quick insight into current market opportunities from investing in Biostem Technologies. Many technical investors use Biostem Technologies stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Biostem Technologies otc stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Biostem daily returns and investor perception about the current price of Biostem Technologies as well as its diversification or hedging effects on your existing portfolios.
Biostem |
Filed transaction by Werewolf Therapeutics Officer Chief Scientific Officer. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Biostem Technologies Fundamental Analysis
We analyze Biostem Technologies' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biostem Technologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biostem Technologies based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Asset
Current Asset Comparative Analysis
Biostem Technologies is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Biostem Technologies Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Biostem Technologies otc stock to make a market-neutral strategy. Peer analysis of Biostem Technologies could also be used in its relative valuation, which is a method of valuing Biostem Technologies by comparing valuation metrics with similar companies.
Peers
Biostem Technologies Related Equities
| CING | Cingulate | 11.60 | ||||
| MNPR | Monopar Therapeutics | 3.64 | ||||
| GNLX | Genelux Common | 1.18 | ||||
| GNFT | Genfit | 1.91 | ||||
| IKNA | Ikena Oncology | 2.50 | ||||
| CNTB | Connect Biopharma | 3.57 | ||||
| HOWL | Werewolf Therapeutics | 4.17 | ||||
| CCCC | C4 Therapeutics | 4.43 | ||||
| DYAI | Dyadic International | 4.62 | ||||
| EWTX | Edgewise Therapeutics | 5.00 | ||||
| TARA | Protara Therapeutics | 5.92 | ||||
| CELC | Celcuity LLC | 6.14 | ||||
| HCWB | HCW Biologics | 7.50 | ||||
| OVID | Ovid Therapeutics | 9.89 |
Other Information on Investing in Biostem OTC Stock
Biostem Technologies financial ratios help investors to determine whether Biostem OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biostem with respect to the benefits of owning Biostem Technologies security.